Jonathan I. Silverberg, MD, PhD, MPH - Test Your Knowledge of New and Emerging Therapies for Moderate to Severe Atopic Dermatitis: Latest Evidence and Clinical Potential

Go online to PeerView.com/FXS860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. In this activity, an expert in dermatology discusses new
and emerging therapies for patients with moderate to severe atopic
dermatitis. Upon completion of this accredited CE activity,
participants should be better able to: Describe key cytokine
signaling pathways involved in the pathogenesis of atopic
dermatitis (AD) and implications for treatment, Evaluate recent
clinical trial data related to the efficacy and safety of new and
emerging treatment options (eg, JAK inhibitors) for moderate to
severe AD, Treat AD in accordance with current evidence and
guidelines, identifying patients with moderate to severe disease
who would likely derive benefit from novel therapeutic options,
Discuss evidence and recommendations on the immunization and
monitoring of patients with AD who are candidates for, or
receiving, biological or small-molecule targeted immunomodulatory
therapies.